Chemistry:Decoglurant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C21H11F6N5 |
| Molar mass | 447.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]
See also
References
- ↑ 1.0 1.1 "Roche – Pipeline". 2014. http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm.
- ↑ 2.0 2.1 "Roche Group Development Pipeline". 2014. http://www.roche.com/irp1q14e-annex.pdf.
- ↑ "Roche – Pipeline". 2015. http://www.roche.com/irp150128-annex.pdf.
- ↑ "The Secret Life of ketamine". The Pharmaceutical Journal 294 (7854/5). March 2015. http://www.pharmaceutical-journal.com/news-and-analysis/features/the-secret-life-of-ketamine/20068151.article.
External links
 |  |
